Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

Akili logo

About Akili Stock (NASDAQ:AKLI)

Advanced Chart

Key Stats

Today's Range
$0.43
$0.43
50-Day Range
$0.42
$0.44
52-Week Range
$0.19
$1.25
Volume
N/A
Average Volume
2.20 million shs
Market Capitalization
$34.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

AKLI Stock News Headlines

The DeepSeek Moment
“Market Wizard” Larry Benedict Is Recommending 0DTE Trades! Zero-days-to-expiration trades are “sweeping the market,” according to The Wall Street Journal. Why? Because they offer one of the only ways to potentially make massive, 24-hour gains – throughout the year. For the past few years, former hedge fund manager Larry Benedict has been sharing a version of these trades with some of his readers with incredible success. He’s delivered a 79.5% win rate, and everyday folks have reported making huge sums. On Wednesday, February 19th, at 8 p.m. ET, he’s going to show how to place zero-day trades on fast-moving tech stocks like Nvidia and Tesla.
See More Headlines

AKLI Stock Analysis - Frequently Asked Questions

Akili, Inc. (NASDAQ:AKLI) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.04. The firm had revenue of $0.11 million for the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII) and uniQure (QURE).

Company Calendar

Last Earnings
5/11/2023
Today
2/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Net Income
$-59,490,000.00
Net Margins
-2,492.04%
Pretax Margin
-2,489.32%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Book Value
$0.75 per share

Miscellaneous

Free Float
70,776,000
Market Cap
$34.01 million
Optionable
Optionable
Beta
1.72
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:AKLI) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners